DDInter1268 DDInter704
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023.
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Zinc sulfate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Clostridium tetani toxoid antigen (formaldehyde inactivated) {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) FKBP1A
FKBP1A {u} (Gene) is bound by {v} (Compound) Everolimus
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) upregulates {v} (Gene) NOTCH1
NOTCH1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Natalizumab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Everolimus (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) binds FKBP1A (Gene) and FKBP1A (Gene) is bound by Everolimus (Compound)
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Everolimus (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is upregulated by Everolimus (Compound)